Belite Bio, Inc
Financials
Valuation Metrics
Belite Bio, Inc's Market Cap is $6.83B. At end of 2025 it was $5.36B. Ranked #1133 of 3,121 in US market (top 36%), #371 of 1,463 on NASDAQ (top 25%), #60 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.83B | US#1,133/3,121 Sec#60/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-102M | US—/3,121 Sec—/266 |
| Total Assets | $792M | US#2,577/3,121 Sec#121/266 |
| Net Assets | $777M | US#1,944/3,121 Sec#80/266 |
| Employees | 41 | US#2,735/3,121 Sec#215/266 |
| Value | ||
| P/B | 8.79x | US#2,580/3,121 Sec#190/266 |
| FCF Yield | -0.00% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -13.18% | US#2,413/3,121 Sec#86/266 |
| ROA | -12.93% | US#2,714/3,121 Sec#109/266 |
| Financial Health | ||
| Debt Ratio | 1.92% | US#17/3,121 Sec#4/266 |
| Total Debt | $0.00 | US—/3,121 Sec—/266 |
| FCF | $-10563.00 | US#2,318/3,121 Sec#86/266 |
| Cash | $0.00 | US—/3,121 Sec—/266 |
| Current Ratio | 33.56x | US#75/3,121 Sec#9/266 |
| Performance | ||
| 1Y Return | 133.36% | US#136/3,121 Sec#48/266 |
| 1M Return | 4.79% | US#504/3,121 Sec#56/266 |
| From 52W High | -14.82% | US#1,120/3,121 Sec#75/266 |
| 1Y MDD | -29.10% | US#1,351/3,121 Sec#85/266 |
| Trading | ||
| Volume | 103,388 shares | US#2,902/3,121 Sec#260/266 |
| Trading Value | $18M | US#1,974/3,121 Sec#154/266 |
| Per Share | ||
| EPS | $-2.55 | US—/3,121 Sec—/266 |
| BPS | $19.37 | US#1,270/3,121 Sec#30/266 |
Company Info
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.